U.S. Markets closed

Portola Pharmaceuticals, Inc. (PTLA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
53.99+0.77 (+1.45%)
At close: 4:00PM EDT
People also watch
CLVSPBYITSROPTCTOPHT

Portola Pharmaceuticals, Inc.

270 East Grand Avenue
South San Francisco, CA 94080
United States
650-246-7000
http://www.portola.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees163

Key Executives

NameTitlePayExercisedAge
Mr. William LisCEO, Pres & Director740.85kN/A53
Ms. Mardi C. DierCFO & Exec. VP603.43k354.25k53
Dr. John T. Curnutte M.D., Ph.D.Exec. VP of R&D575.19kN/A65
Mr. Tao FuChief Commercial & Bus. Officer and Exec. VP580.72kN/A45
Mr. Jeet MahalVP of Bus. Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Dermavant Sciences GmbH. The company was founded in 2003 and is headquartered in South San Francisco, California.

Corporate Governance

Portola Pharmaceuticals, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 7. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.